INFeD® improved the hemoglobin response to erythropoietic therapy in have been reported after administration of iron dextran injection, the drug should be. iron dextran – Drug Summary. Jump to INFeD Intramuscular Inj Sol: 1mL, 50mg . INFeD: INFeD is administered by intramuscular or intravenous injection. Allergan, Inc.: Intravenous or intramuscular injections of INFeD are indicated for treatment of patients with documented iron deficiency in whom.
|Published (Last):||25 October 2011|
|PDF File Size:||7.17 Mb|
|ePub File Size:||10.93 Mb|
|Price:||Free* [*Free Regsitration Required]|
Recipient’s Email Separate multiple email address with a comma Please enter valid email address Recipient’s email infer required. Children 5 — 15 kg 11 — 33 lbs: Minor Inadequate iron stores will interfere with the insdrt response to epoetin alfa e. Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration paclage INFeD. If inssert patient is standing, inject iron dextran into the buttock opposite the weight-bearing leg. If test dose uneventful, infuse the remainder of the total calculated dose IV over 2 to 6 hours.
In the study of infants with the gestational age of about 28 weeks, a dose of 0. Iron Replacement for Blood Loss: Deferoxamine is indicated as a treatment of iron toxicity or overdose. Parenteral iron supplement of ferric oxyhydroxide complexed with dextrans; rapidly repletes iron stores in deficiency from anemia or blood loss; sometimes associated with severe hypersensitivity.
A test dose should be given prior to administration of the initial therapeutic dose. Am J Kid Dis. Inject via slow IV at a gradual rate not to exceed 50 mg 1 mL per minute for adults; take care to inject dosage very slowly in children insertt infants. INFeD is administered by intramuscular or intravenous injection.
Iron dextran is classified in FDA pregnancy risk category C. Patients with a significant history of allergies e. Once the infusion is completed, flush vein with NS injection.
Infants 4 months and older weighing less than 5 kg. Normal erythropoiesis is dependent on the concentration of iron and erythropoietin available in the plasma. Although there are significant variations in body build and weight distribution among males and females, the accompanying table and formula represent a convenient means for estimating the total iron required.
To avoid staining of subcutaneous tissue, use the Z-track technique of injection. It would be illogical for a patient to receive both iron supplementation and deferasirox simultaneously.
Adults, Adolescents, Children, and Infants 4 months and older. Related Drug Information Packag Summary. Give INFeD test doses gradually over at least 30 seconds. If no adverse reactions are observed, INFeD can be given according to the following schedule until the calculated total amount required has been reached. Serum iron, total iron binding capacity TIBC and percent saturation of transferrin are other important tests for detecting and monitoring the iron deficient state.
Observe patient for at least 1 hour after test dose administration.
INFeD (iron dextran) dose, indications, adverse effects, interactions from
If there is no reaction after 1 hour continue. Distribution of iron dextran following intramuscular or intravenous injection involves uptake by reticuloendothelial cells of the liver, spleen, and bone marrow.
Facilities for cardiopulmonary resuscitation and personnel trained in the detection and treatment of anaphylactoid reactions must be available during administration. If a breast-feeding infant experiences an adverse effect related to insedt maternally ingested drug, healthcare providers are encouraged to report the adverse effect to the FDA.
Specific guidelines for dosage adjustments in hepatic impairment are not available. Paxkage the patient for at least 1 hour after test dose administration. Pediatric Use Alternatively the total dose may be calculated: Serious anaphylactoid reactions require appropriate resuscitative measures.
An In Vitro Study.
Iron dextran (INFeD)
Subcutaneous injection of iron dextran results in slow absorption and staining of subcutaneous tissue. Non-iron deficient animal data rats, mice, dogs and monkeys reveal that iron dextran crosses the placenta. This total iron requirement reflects the amount of iron needed to restore hemoglobin concentration to normal or near normal levels plus an additional allowance to provide adequate replenishment of iron stores in most individuals with moderately or severely reduced levels of hemoglobin.
Iron dextran is not FDA-approved iinsert be administered as a total dose infusion. Transferrin eventually becomes available for reuse.
Do not administer iron during dimercaprol treatment. The chelate is excreted in the urine and in the feces via bile. Parenterally administered iron does not give a faster response compared to oral administration, therefore, the rate of recovery from anemia should be the same.
INFeD is given undiluted at a insegt gradual rate not to exceed 50 mg 1 mL per minute. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.
Fatal anaphylactic reactions are possible. The contribution of iron to infectious processes is unclear, but iron dextran should not be administered during packgae acute phase of infectious renal disease manufacturer’s information.
The table and accompanying formula are applicable for dosage determinations only in patients with iron deficiency anemia; they are not to be used for dosage determinations in patients requiring iron replacement for blood loss.
The formula shown below is based on the approximation that 1 mL of normocytic, normochromic red packagr contains 1 mg of elemental iron:. Fatal anaphylactoid packkage have occurred during the parenteral administration of iron dextran.
Parenteral iron preparations e. Iron Deficiency Anemia are not applicable for simple iron replacement values. Total dosage with iron dextran must be individualized according to the patients age, weight, and the degree of the iron-deficiency infde.
The factors that affect the risk for anaphylactic-type reactions to iron dextran products are not fully known but limited clinical data inseet the risk may be increased among patients with a history of drug allergy or multiple drug allergies.